Myriad and Pfizer Signs a Service Agreement for Testing of BRCA-Mutated Triple Negative Breast Cancer
Shots:
- Myriad to provide BRACAnalysis CDx testing device in P-II study conducted to evaluate Pfizer’s talazoparib for neo-adjuvant treatment of germline BRCA-mutated triple negative breast cancer
- BRACAnalysis CDx is an IVD device used for qualitative detection and classification of protein coding regions & intron/exon boundaries of BRCA1 and BRCA2 gene
- In April- 2015 Myriad and AstraZeneca also entered into agreement for evaluating Lynparza in patients with metastatic pancreatic cancer using Myriad’s BRACAnalysis CDx test
Ref: Myriad | Image: Forbes
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com